FDA Inspection
AstraZeneca Pharmaceuticals, LPAstraZeneca Pharmaceuticals, LP – FDA Inspection, Mar 29, 2016
Record Details
This FDA Inspection record concerns AstraZeneca Pharmaceuticals, LP, with an inspection on March 29, 2016, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- March 29, 2016
- Product Type
- Drugs
View Company Profile
ID · 65a34f00-14ed-4660-a63b-a2f0505b795a
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 963627
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of AstraZeneca Pharmaceuticals, LP
4| Date | Classification | Office | Project area |
|---|---|---|---|
| April 3, 2026 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 5, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 30, 2017 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 18, 2015 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for AstraZeneca Pharmaceuticals, LP
- FDA Inspection 1312298 - 2026-04-03
- FDA Inspection 1047488 - 2018-03-05
- FDA Inspection 998797 - 2017-01-30
- FDA Inspection 954660 - 2015-12-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.